Moscow: Russia's sovereign wealth fund said on Wednesday it will supply India's Dr Reddy's Laboratories with 100 million doses of the Sputnik-V vaccine against Covid-19 once it receives regulatory approval in India.
Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with the Indian firm. Both the trials and supply deal depend on domestic regulatory approval.
The Russian Direct Investment Fund (RDIF) has already inked vaccine supply deals with Kazakhstan, Brazil and Mexico and has reached a manufacturing partnership agreement with India to produce 300 million doses of the Sputnik-V vaccine there.
Russia has billed Sputnik-V as the first vaccine against coronavirus to be registered in the world. Large-scale trials, known as Phase III, involving at least 40,000 people, were launched in Russia on August 26 but have yet to be completed.